Journal of immune based therapies and vaccines最新文献

筛选
英文 中文
An HIV/AIDS Prophylactic vaccine is possible. 艾滋病毒/艾滋病预防疫苗是可能的。
Journal of immune based therapies and vaccines Pub Date : 2007-12-19 DOI: 10.1186/1476-8518-5-12
Qiu Zhong, Ronald B Luftig
{"title":"An HIV/AIDS Prophylactic vaccine is possible.","authors":"Qiu Zhong,&nbsp;Ronald B Luftig","doi":"10.1186/1476-8518-5-12","DOIUrl":"https://doi.org/10.1186/1476-8518-5-12","url":null,"abstract":"<p><p> One needs to think outside of the box, as one of us (Ronald B Luftig) learned from many years as a mathematician, and a biophysicist.In this short Review, the need to focus on producing high levels of neutralizing antibodies (NAbs) to incoming and conformationally altered virus after it has bound to CD4+ cells is essential.Increasing the number of gp120 molecules on the surface of L-2 particles, could allow for an enhanced number of NAbs.The attempt at increasing CD8+ T cell responses in recent vaccine trials has not worked perhaps because it may have allowed HIV to enter into remote sanctuaries. Our approach focuses on increasing NAbs, before high levels of CD8+ T cells are produced.</p>","PeriodicalId":84998,"journal":{"name":"Journal of immune based therapies and vaccines","volume":"5 ","pages":"12"},"PeriodicalIF":0.0,"publicationDate":"2007-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/1476-8518-5-12","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"27129766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rapid generation of an anthrax immunotherapeutic from goats using a novel non-toxic muramyl dipeptide adjuvant. 利用新型无毒氨酰二肽佐剂从山羊体内快速产生炭疽免疫疗法。
Journal of immune based therapies and vaccines Pub Date : 2007-10-22 DOI: 10.1186/1476-8518-5-11
Cassandra D Kelly, Chris O'Loughlin, Frank B Gelder, Johnny W Peterson, Laurie E Sower, Nick M Cirino
{"title":"Rapid generation of an anthrax immunotherapeutic from goats using a novel non-toxic muramyl dipeptide adjuvant.","authors":"Cassandra D Kelly, Chris O'Loughlin, Frank B Gelder, Johnny W Peterson, Laurie E Sower, Nick M Cirino","doi":"10.1186/1476-8518-5-11","DOIUrl":"10.1186/1476-8518-5-11","url":null,"abstract":"<p><strong>Background: </strong>There is a clear need for vaccines and therapeutics for potential biological weapons of mass destruction and emerging diseases. Anthrax, caused by the bacterium Bacillus anthracis, has been used as both a biological warfare agent and bioterrorist weapon previously. Although antibiotic therapy is effective in the early stages of anthrax infection, it does not have any effect once exposed individuals become symptomatic due to B. anthracis exotoxin accumulation. The bipartite exotoxins are the major contributing factors to the morbidity and mortality observed in acute anthrax infections.</p><p><strong>Methods: </strong>Using recombinant B. anthracis protective antigen (PA83), covalently coupled to a novel non-toxic muramyl dipeptide (NT-MDP) derivative we hyper-immunized goats three times over the course of 14 weeks. Goats were plasmapheresed and the IgG fraction (not affinity purified) and F(ab')2 derivatives were characterized in vitro and in vivo for protection against lethal toxin mediated intoxication.</p><p><strong>Results: </strong>Anti-PA83 IgG conferred 100% protection at 7.5 mug in a cell toxin neutralization assay. Mice exposed to 5 LD50 of Bacillus anthracis Ames spores by intranares inoculation demonstrated 60% survival 14 d post-infection when administered a single bolus dose (32 mg/kg body weight) of anti-PA83 IgG at 24 h post spore challenge. Anti-PA83 F(ab')2 fragments retained similar neutralization and protection levels both in vitro and in vivo.</p><p><strong>Conclusion: </strong>The protection afforded by these GMP-grade caprine immunotherapeutics post-exposure in the pilot murine model suggests they could be used effectively to treat post-exposure, symptomatic human anthrax patients following a bioterrorism event. These results also indicate that recombinant PA83 coupled to NT-MDP is a potent inducer of neutralizing antibodies and suggest it would be a promising vaccine candidate for anthrax. The ease of production, ease of covalent attachment, and immunostimulatory activity of the NT-MDP indicate it would be a superior adjuvant to alum or other traditional adjuvants in vaccine formulations.</p>","PeriodicalId":84998,"journal":{"name":"Journal of immune based therapies and vaccines","volume":"5 ","pages":"11"},"PeriodicalIF":0.0,"publicationDate":"2007-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2104530/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"27062653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Specific antibody response of mice after immunization with COS-7 cell derived avian influenza virus (H5N1) recombinant proteins. COS-7细胞源性禽流感病毒(H5N1)重组蛋白免疫小鼠后的特异性抗体反应
Journal of immune based therapies and vaccines Pub Date : 2007-10-03 DOI: 10.1186/1476-8518-5-10
Navin Horthongkham, Tananun Srihtrakul, Niracha Athipanyasilp, Sontana Siritantikorn, Wannee Kantakamalakul, Yong Poovorawan, Ruengpung Sutthent
{"title":"Specific antibody response of mice after immunization with COS-7 cell derived avian influenza virus (H5N1) recombinant proteins.","authors":"Navin Horthongkham,&nbsp;Tananun Srihtrakul,&nbsp;Niracha Athipanyasilp,&nbsp;Sontana Siritantikorn,&nbsp;Wannee Kantakamalakul,&nbsp;Yong Poovorawan,&nbsp;Ruengpung Sutthent","doi":"10.1186/1476-8518-5-10","DOIUrl":"https://doi.org/10.1186/1476-8518-5-10","url":null,"abstract":"<p><p> To develop avian influenza H5N1 recombinant protein, the hemagglutinin (HA), neuraminidase (NA), matrix (M), and non-structural (NS1) of avian influenza H5N1 isolates from Thailand were engineered to be expressed in prokaryotic (E. coli) and mammalian cell (COS-7) system. The plasmid pBAD-His and pSec-His were used as vectors for these inserted genes. Mice immunized with purified recombinant proteins at concentration 50-250 mug intramuscularly with Alum adjuvant at week 0, week 2, and week 3 showed a good immunogenicity measured by ELISA and neutralization assay. The HA and NS recombinant proteins produced in COS-7 cells can induce specific antibody titer detected by neutralization assay significantly higher than corresponding recombinant proteins produced in E. coli system. The antibody produced in immunized mice could neutralize heterologous avian influenza virus determined by micro-neutralization assay. This study shows that avian influenza virus H5N1 recombinant proteins produced in mammalian cell system were able to induce neutralizing antibody response.</p>","PeriodicalId":84998,"journal":{"name":"Journal of immune based therapies and vaccines","volume":"5 ","pages":"10"},"PeriodicalIF":0.0,"publicationDate":"2007-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/1476-8518-5-10","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"27025532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
CTLA-4 blockade during dendritic cell based booster vaccination influences dendritic cell survival and CTL expansion. 树突状细胞增强疫苗接种过程中CTLA-4阻断影响树突状细胞存活和CTL扩增。
Journal of immune based therapies and vaccines Pub Date : 2007-07-29 DOI: 10.1186/1476-8518-5-9
Anders E Pedersen, Franca Ronchese
{"title":"CTLA-4 blockade during dendritic cell based booster vaccination influences dendritic cell survival and CTL expansion.","authors":"Anders E Pedersen,&nbsp;Franca Ronchese","doi":"10.1186/1476-8518-5-9","DOIUrl":"https://doi.org/10.1186/1476-8518-5-9","url":null,"abstract":"<p><p>Dendritic cells (DCs) are potent antigen-presenting cells and critical for the priming of CD8+ T cells. Therefore the use of these cells as adjuvant cells has been tested in a large number of experimental and clinical vaccination studies, in particular cancer vaccine studies. A number of protocols are emerging that combine vaccination with CTL expanding strategies, such as e.g. blockade of CTLA-4 signalling. On the other hand, the lifespan and in vivo survival of therapeutic DCs have only been addressed in a few studies, although this is of importance for the kinetics of CTL induction during vaccination. We have previously reported that DCs loaded with specific antigens are eliminated by antigen specific CTLs in vivo and that this elimination affects the potential for in vivo CTL generation. We now show that CTLA-4 blockade increases the number of DC vaccine induced LCMV gp33 specific CTLs and the lysis of relevant in vivo targets. However, the CTLA-4 blockage dependent expansion of CTLs also affect DC survival during booster DC injections and our data suggest that during a booster DC vaccine, the largest increase in CTL levels is already obtained during the first vaccination.</p>","PeriodicalId":84998,"journal":{"name":"Journal of immune based therapies and vaccines","volume":"5 ","pages":"9"},"PeriodicalIF":0.0,"publicationDate":"2007-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/1476-8518-5-9","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"26857061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 8
Age-related waning of in vitro Interferon-gamma levels against r32kDaBCG in BCG vaccinated children. 卡介苗接种儿童抗r32kDaBCG体外干扰素γ水平的年龄相关性减弱
Journal of immune based therapies and vaccines Pub Date : 2007-06-07 DOI: 10.1186/1476-8518-5-8
B Anuradha, C M Santosh, V Hari Sai Priya, G Suman Latha, K J R Murthy, Valluri Vijaya Lakshmi
{"title":"Age-related waning of in vitro Interferon-gamma levels against r32kDaBCG in BCG vaccinated children.","authors":"B Anuradha,&nbsp;C M Santosh,&nbsp;V Hari Sai Priya,&nbsp;G Suman Latha,&nbsp;K J R Murthy,&nbsp;Valluri Vijaya Lakshmi","doi":"10.1186/1476-8518-5-8","DOIUrl":"https://doi.org/10.1186/1476-8518-5-8","url":null,"abstract":"<p><strong>Background: </strong>Mycobacterium bovis BCG vaccine has displayed inconsistent efficacy in different trials conducted in various geographical regions. Nevertheless, it significantly reduces the risk of severe childhood tuberculosis and continues to be used to prevent tuberculosis in many countries. Many studies revealed that efficacy of vaccine wanes with age. Most of the studies were based on in vivo and in vitro responses to tuberculin. With the advent of newer tests such as in vitro interferon-gamma assays and identification of potent immunogenic mycobacterial proteins there is a need to corroborate the observations. This study aims at ascertaining the need for a booster at a later age as indicated by in vitro release of IFN-gamma while evaluating Ag85A as an antigen.</p><p><strong>Methods: </strong>Ninety healthy children who were without any clinical evidence of the disease, 45 with a BCG-scar and the remaining 45 without scar and 25 with tuberculosis were included in the study. The incidence of TB was analyzed in 216 children attending a DOTS clinic during 1996-2005. CD3+, CD4+ and CD8+ cell counts were measured by Flow cytometry. r32kDaBCG (Ag85A-BCG) protein was used to stimulate T cells in in vitro T cell responses and interferon-gamma (IFN-gamma) cytokine levels in the supernatants were measured by ELISA.</p><p><strong>Results: </strong>High incidence of TB was observed in age group 13-14 years followed by children in the age group 10-12 years (Chi-square 242.22; p < 0.000). T cell subsets were within the normal range in all subjects. 79% of vaccinated children showed positive proliferative responses with a mean SI value of 4.98 +/- 1.99 while only 39% of the unvaccinated and 58% of the tuberculosis children showed positive responses with mean values of 2.9 +/- 1.6 (p < 0.001) and 2.9 +/- 1.7(p < 0.057), respectively. The stimulation indices in vaccinated children decreased in the older children concurring with an increase in the incidence of TB.</p><p><strong>Conclusion: </strong>Significantly high levels of in vitro IFN-gamma demonstrated in BCG vaccinated children in our study substantiate the observation that BCG is effective in children, but the effect may wane with age. The immunity could be boosted using modified r32kDa (Ag85A) of BCG.</p>","PeriodicalId":84998,"journal":{"name":"Journal of immune based therapies and vaccines","volume":"5 ","pages":"8"},"PeriodicalIF":0.0,"publicationDate":"2007-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/1476-8518-5-8","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"26765970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 17
Phenotype and in vitro function of mature MDDC generated from cryopreserved PBMC of cancer patients are equivalent to those from healthy donors. 从冷冻保存的癌症患者PBMC中产生的成熟MDDC的表型和体外功能与来自健康供体的MDDC相当。
Journal of immune based therapies and vaccines Pub Date : 2007-05-03 DOI: 10.1186/1476-8518-5-7
Smita A Ghanekar, Sonny Bhatia, Joyce J Ruitenberg, Corazon DeLa Rosa, Mary L Disis, Vernon C Maino, Holden T Maecker, Cory A Waters
{"title":"Phenotype and in vitro function of mature MDDC generated from cryopreserved PBMC of cancer patients are equivalent to those from healthy donors.","authors":"Smita A Ghanekar,&nbsp;Sonny Bhatia,&nbsp;Joyce J Ruitenberg,&nbsp;Corazon DeLa Rosa,&nbsp;Mary L Disis,&nbsp;Vernon C Maino,&nbsp;Holden T Maecker,&nbsp;Cory A Waters","doi":"10.1186/1476-8518-5-7","DOIUrl":"https://doi.org/10.1186/1476-8518-5-7","url":null,"abstract":"<p><strong>Background: </strong>Monocyte-derived-dendritic-cells (MDDC) are the major DC type used in vaccine-based clinical studies for a variety of cancers. In order to assess whether in vitro differentiated MDDC from cryopreserved PBMC of cancer patients are functionally distinct from those of healthy donors, we compared these cells for their expression of co-stimulatory and functional markers. In addition, the effect of cryopreservation of PBMC precursors on the quality of MDDC was also evaluated using samples from healthy donors.</p><p><strong>Methods: </strong>Using flow cytometry, we compared normal donors and cancer patients MDDC grown in the presence of GM-CSF+IL-4 (immature MDDC), and GM-CSF+IL-4+TNFalpha+IL-1beta+IL-6+PGE-2 (mature MDDC) for (a) surface phenotype such as CD209, CD83 and CD86, (b) intracellular functional markers such as IL-12 and cyclooxygenase-2 (COX-2), (c) ability to secrete IL-8 and IL-12, and (d) ability to stimulate allogeneic and antigen-specific autologous T cells.</p><p><strong>Results: </strong>Cryopreservation of precursors did affect MDDC marker expression, however, only two markers, CD86 and COX-2, were significantly affected. Mature MDDC from healthy donors and cancer patients up-regulated the expression of CD83, CD86, frequencies of IL-12+ and COX-2+ cells, and secretion of IL-8; and down-regulated CD209 expression relative to their immature counterparts. Compared to healthy donors, mature MDDC generated from cancer patients were equivalent in the expression of nearly all the markers studied and importantly, were equivalent in their ability to stimulate allogeneic and antigen-specific T cells in vitro.</p><p><strong>Conclusion: </strong>Our data show that cryopreservation of DC precursors does not significantly affect the majority of the MDDC markers, although the trends are towards reduced expression of co-stimulatory makers and cytokines. In addition, monocytes from cryopreserved PBMC of cancer patients can be fully differentiated into mature DC with phenotype and function equivalent to those derived from healthy donors.</p>","PeriodicalId":84998,"journal":{"name":"Journal of immune based therapies and vaccines","volume":"5 ","pages":"7"},"PeriodicalIF":0.0,"publicationDate":"2007-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/1476-8518-5-7","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"26703217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 19
A phase I, randomized study of combined IL-2 and therapeutic immunisation with antiretroviral therapy. 一项I期随机研究,联合IL-2和抗逆转录病毒治疗性免疫。
Journal of immune based therapies and vaccines Pub Date : 2007-04-11 DOI: 10.1186/1476-8518-5-6
Gareth Ad Hardy, Nesrina Imami, Mark R Nelson, Ann K Sullivan, Ron Moss, Marlén Mi Aasa-Chapman, Brian Gazzard, Frances M Gotch
{"title":"A phase I, randomized study of combined IL-2 and therapeutic immunisation with antiretroviral therapy.","authors":"Gareth Ad Hardy,&nbsp;Nesrina Imami,&nbsp;Mark R Nelson,&nbsp;Ann K Sullivan,&nbsp;Ron Moss,&nbsp;Marlén Mi Aasa-Chapman,&nbsp;Brian Gazzard,&nbsp;Frances M Gotch","doi":"10.1186/1476-8518-5-6","DOIUrl":"https://doi.org/10.1186/1476-8518-5-6","url":null,"abstract":"<p><strong>Background: </strong>Fully functional HIV-1-specific CD8 and CD4 effector T-cell responses are vital to the containment of viral activity and disease progression. These responses are lacking in HIV-1-infected patients with progressive disease. We attempted to augment fully functional HIV-1-specific CD8 and CD4 effector T-cell responses in patients with advanced chronic HIV-1 infection.</p><p><strong>Design: </strong>Chronically infected patients with low CD4 counts T-cell counts who commenced antiretroviral therapy (ART) were subsequently treated with combined interleukin-2 and therapeutic vaccination.</p><p><strong>Methods: </strong>Thirty six anti-retroviral naive patients were recruited and initiated on combination ART for 17 weeks before randomization to: A) ongoing ART alone; B) ART with IL-2 twice daily for 5 days every four weeks starting at week 17 for 3 cycles; C) ART with IL-2 as in group B and Remune HIV-1 vaccine administered once every 3 months, starting at week 17; and D) ART with Remune vaccine as in group C. Patients were studied for 65 weeks following commencement of ART, with an additional prior 6 week lead-in observation period. CD4 and CD8 T-cell counts, evaluations of HIV-1 RNA levels and proliferative responses to recall and HIV-1 antigens were complemented with assessment of IL-4-secretion alongside quantification of anti-HIV-1 CD8 T-cell responses and neutralizing antibody titres.</p><p><strong>Results: </strong>Neither IL-2 nor Remune vaccination induced sustained HIV-1-specific T-cell responses. However, we report an inverse relationship between HIV-1-specific proliferative responses and IL-4 production which continuously increased in patients receiving immunotherapy, but not patients receiving ART alone.</p><p><strong>Conclusion: </strong>Induction of HIV-1-specific cell-mediated responses is a major challenge in chronically HIV-1-infected patients even when combining immunisation with IL-2 therapy. An antigen-specific IL-4-associated suppressive response may play a role in attenuating HIV-specific responses.</p>","PeriodicalId":84998,"journal":{"name":"Journal of immune based therapies and vaccines","volume":"5 ","pages":"6"},"PeriodicalIF":0.0,"publicationDate":"2007-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/1476-8518-5-6","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"26660596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 93
IMP321 (sLAG-3), an immunopotentiator for T cell responses against a HBsAg antigen in healthy adults: a single blind randomised controlled phase I study. IMP321 (sLAG-3),一种针对健康成人HBsAg抗原的T细胞应答免疫增强剂:一项单盲随机对照I期研究
Journal of immune based therapies and vaccines Pub Date : 2007-03-29 DOI: 10.1186/1476-8518-5-5
Chrystelle Brignone, Caroline Grygar, Manon Marcu, Gaëlle Perrin, Frédéric Triebel
{"title":"IMP321 (sLAG-3), an immunopotentiator for T cell responses against a HBsAg antigen in healthy adults: a single blind randomised controlled phase I study.","authors":"Chrystelle Brignone,&nbsp;Caroline Grygar,&nbsp;Manon Marcu,&nbsp;Gaëlle Perrin,&nbsp;Frédéric Triebel","doi":"10.1186/1476-8518-5-5","DOIUrl":"https://doi.org/10.1186/1476-8518-5-5","url":null,"abstract":"<p><strong>Background: </strong>LAG-3 (CD223) is a natural high affinity ligand for MHC class II. The soluble form (sLAG-3) induces maturation of monocyte-derived dendritic cells in vitro and is used as a potent Th1-like immune enhancer with many antigens in animal models. To extend this observation to human, a proof of concept study was conducted with a clinical-grade sLAG-3, termed IMP321, coinjected with alum-non-absorbed recombinant hepatitis B surface antigen.</p><p><strong>Methods: </strong>In a randomised, single blind controlled phase I dose escalation study, 48 seronegative healthy volunteers aged 18-55 years were vaccinated at 0, 4 and 8 weeks by subcutaneous injection with 10 microg HBsAg mixed with saline (control) or with IMP321 at one of four doses (3, 10, 30 and 100 microg). To evaluate the efficacy of this three injections over 2 months immunization protocol, an additional control group was injected with the commercial vaccine Engerix-B.</p><p><strong>Results: </strong>IMP321 was very well tolerated. Indeed, a lower incidence of adverse events was reported from the HBsAg plus IMP321 groups than from the Engerix-B group. HBsAg-specific antibody responses (anti-HBs) appeared sooner and were higher at 8 and 12 weeks in IMP321 recipients compared to HBsAg control subjects. More importantly, increased numbers of responders to HBsAg were found in IMP321 recipients compared HBsAg group, as revealed by higher post-vaccination frequencies of CD4 Th1 or CD8 Tc1 antigen specific T cells. IMP321 induced CD4 Th1 antigen-specific T cells in some of these naïve individuals after only one injection, especially in the 10 and 30 microg dose groups.</p><p><strong>Conclusion: </strong>IMP321 as an adjuvant to HBsAg was well-tolerated and enhanced T cell response vaccine immunogenicity (i.e. induced both CD4 Th1 and CD8 Tc1 antigen-specific T cells). This latter property has allowed the development of IMP321 as an immunopotentiator for therapeutic vaccines.</p>","PeriodicalId":84998,"journal":{"name":"Journal of immune based therapies and vaccines","volume":"5 ","pages":"5"},"PeriodicalIF":0.0,"publicationDate":"2007-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/1476-8518-5-5","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"26233777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 32
Evaluation of a recombinant human gelatin as a substitute for a hydrolyzed porcine gelatin in a refrigerator-stable Oka/Merck live varicella vaccine. 重组人明胶替代水解猪明胶用于冷藏稳定型Oka/Merck水痘活疫苗的评价。
Journal of immune based therapies and vaccines Pub Date : 2007-02-23 DOI: 10.1186/1476-8518-5-4
Vladimir Liska, Stacey A Bigert, Philip S Bennett, David Olsen, Robert Chang, Carl J Burke
{"title":"Evaluation of a recombinant human gelatin as a substitute for a hydrolyzed porcine gelatin in a refrigerator-stable Oka/Merck live varicella vaccine.","authors":"Vladimir Liska,&nbsp;Stacey A Bigert,&nbsp;Philip S Bennett,&nbsp;David Olsen,&nbsp;Robert Chang,&nbsp;Carl J Burke","doi":"10.1186/1476-8518-5-4","DOIUrl":"https://doi.org/10.1186/1476-8518-5-4","url":null,"abstract":"<p><strong>Background: </strong>The labile nature of live, attenuated varicella-zoster virus (Oka/Merck) requires robust stabilization during virus bulk preparation and vaccine manufacturing in order to preserve potency through storage and administration. One stabilizing ingredient used in a varicella-zoster virus (VZV) vaccine is hydrolyzed porcine gelatin which represents the major protein/peptide-based excipient in the vaccine formulation.</p><p><strong>Methods: </strong>In this comparative study, a recombinant human gelatin fragment (8.5 kD) was assessed as a potential replacement for hydrolyzed porcine gelatin in an experimental live, attenuated VZV (Oka/Merck) vaccine. VZV (Oka/Merck) was harvested in two formulations prepared with either a hydrolyzed porcine gelatin or a recombinant human gelatin. Moreover, the viral stability in the experimental VZV (Oka/Merck) vaccines was evaluated under accelerated and real-time conditions in a comparative study.</p><p><strong>Results and discussion: </strong>The stabilizing effect of recombinant human gelatin on VZV (Oka/Merck) potency change during vaccine lyophilization was similar to the experimental vaccine containing porcine-derived gelatin. Vaccine viral potency changes were comparable in stabilized VZV (Oka/Merck) formulations containing either hydrolyzed porcine gelatin or recombinant human gelatin. No statistically significant difference in potency stability was observed between the vaccine formulations stored at any of the temperatures tested.</p><p><strong>Conclusion: </strong>The recombinant human gelatin demonstrated similar ability to stabilize the live attenuated VZV (Oka/Merck) in an experimental, refrigerator-stable varicella vaccine when compared to the vaccine preparation formulated with hydrolyzed porcine gelatin used in currently marketed varicella vaccine.</p>","PeriodicalId":84998,"journal":{"name":"Journal of immune based therapies and vaccines","volume":"5 ","pages":"4"},"PeriodicalIF":0.0,"publicationDate":"2007-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/1476-8518-5-4","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"26625675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 11
Improved generation of anti-tumor immunity by antigen dose limitation. 通过限制抗原剂量提高抗肿瘤免疫的产生。
Journal of immune based therapies and vaccines Pub Date : 2007-02-09 DOI: 10.1186/1476-8518-5-2
Joshua D Shofner, Juan G Vasquez, Carole L Berger, Richard L Edelson
{"title":"Improved generation of anti-tumor immunity by antigen dose limitation.","authors":"Joshua D Shofner,&nbsp;Juan G Vasquez,&nbsp;Carole L Berger,&nbsp;Richard L Edelson","doi":"10.1186/1476-8518-5-2","DOIUrl":"https://doi.org/10.1186/1476-8518-5-2","url":null,"abstract":"<p><strong>Background: </strong>The malignant cells of cutaneous T cell lymphoma (CTCL) display immunogenic peptides derived from the clonal T cell receptor (TCR) providing an attractive model for refinement of anti-tumor immunization methodology. To produce a clinically meaningful anti-tumor response, induction of cytotoxic anti-CTCL cells must be maximized while suppressive T regulatory cells (Treg) should be minimized. We have demonstrated that engulfment of apoptotic CTCL cells by dendritic cells (DC) can lead to either CD8 anti-CTCL responses or immunosuppressive Treg induction. Treg generation is favored when the number of apoptotic cells available for ingestion is high.</p><p><strong>Methods: </strong>In this study, we sought to determine whether the balance between immunity and immunosuppression could be shifted towards a CD8 anti-CTCL response by lowering the ratio of apoptotic CTCL cells available for DC ingestion. CTCL cell apoptosis was produced by engagement of the TCR by anti-CD3 antibody affixed to magnetic beads.</p><p><strong>Results: </strong>The physical perturbation inherent in passage through a separation column induced monocytes to differentiate into DC, demonstrated by increased expression of class II and CD86 and decreased expression of the monocyte marker CD14. The immature DC internalized and processed apoptotic CTCL cells and could potentially present the tumor-derived peptides in the context of MHC class I and II. As the number of apoptotic cells increased, there was a dose-dependent increase in the expression of Treg markers CTLA-4, CD25, and FoxP3, with a ratio of apoptotic cell/DC loading of > 10:1 corresponding to the greatest Treg induction. These inducible phenotypic Treg also functionally inhibited CD8-mediated perforin expression in vitro. At lower levels of apoptotic cell/DC loading of < 5:1, there was an expansion of the CD8 T cell compartment with increased perforin expression and increased CTCL cell death, indicating anti-tumor activity.</p><p><strong>Conclusion: </strong>These findings demonstrate that the ratio of apoptotic cells supplied to DC is an important determinant of whether CD8 anti-tumor immunity or immunosuppression is generated.</p>","PeriodicalId":84998,"journal":{"name":"Journal of immune based therapies and vaccines","volume":"5 ","pages":"2"},"PeriodicalIF":0.0,"publicationDate":"2007-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/1476-8518-5-2","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"26545609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信